Q3 Earnings Forecast for biote Issued By B. Riley

biote Corp. (NASDAQ:BTMD) – Equities researchers at B. Riley issued their Q3 2025 EPS estimates for shares of biote in a note issued to investors on Thursday, March 13th. B. Riley analyst J. Van. Sinderen expects that the company will post earnings per share of $0.10 for the quarter. The consensus estimate for biote’s current full-year earnings is $0.75 per share. B. Riley also issued estimates for biote’s Q4 2025 earnings at $0.10 EPS.

Separately, Craig Hallum reduced their price target on biote from $12.00 to $8.00 and set a “buy” rating for the company in a report on Thursday.

biote Stock Performance

Shares of biote stock opened at $3.07 on Friday. The firm has a 50-day simple moving average of $5.01 and a two-hundred day simple moving average of $5.57. biote has a fifty-two week low of $3.04 and a fifty-two week high of $8.44. The company has a market cap of $166.81 million, a P/E ratio of 11.81 and a beta of 1.07.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Wasatch Advisors LP raised its position in shares of biote by 8.4% in the third quarter. Wasatch Advisors LP now owns 1,392,809 shares of the company’s stock valued at $7,772,000 after buying an additional 107,792 shares during the last quarter. Dimensional Fund Advisors LP grew its stake in biote by 0.5% during the 4th quarter. Dimensional Fund Advisors LP now owns 681,524 shares of the company’s stock valued at $4,211,000 after acquiring an additional 3,065 shares in the last quarter. State Street Corp raised its holdings in biote by 13.7% in the 3rd quarter. State Street Corp now owns 475,491 shares of the company’s stock valued at $2,653,000 after acquiring an additional 57,290 shares during the last quarter. Kanen Wealth Management LLC purchased a new position in biote in the 4th quarter worth approximately $1,791,000. Finally, Northern Trust Corp boosted its holdings in shares of biote by 9.9% during the 4th quarter. Northern Trust Corp now owns 288,336 shares of the company’s stock worth $1,782,000 after purchasing an additional 25,873 shares during the last quarter. 21.68% of the stock is owned by hedge funds and other institutional investors.

About biote

biote Corp. operates in practice-building business within the hormone optimization space. It trains physicians and nurse practitioners in hormone optimization using bioidentical hormone replacement pellet therapy in men and women experiencing hormonal imbalance. The company offers Biote Method, a comprehensive end-to-end practice building platform that provides Biote-certified practitioners with the components developed for practitioners in the hormone optimization space comprising Biote Method education, training, and certification services; practice management software that allows Biote-certified practitioners to order, track, and manage hormone optimization product inventory and other administrative requirements; inventory management software to monitor pellet inventory; and information regarding available hormone replacement therapy products, as well as digital and point-of-care marketing support.